Device-detected atrial fibrillation in a large remote-monitored cohort: implications for anticoagulation and need for new pathways of service delivery

[1]  A. León,et al.  Relationship between device-detected burden and duration of atrial fibrillation and risk of ischemic stroke. , 2020, Heart rhythm.

[2]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.

[3]  T. N. Harrison,et al.  Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP-RHYTHM Study , 2018, JAMA cardiology.

[4]  Christophe Leclercq,et al.  2018 ESC Guidelines for the diagnosis and management of syncope , 2018, European heart journal.

[5]  Rajiv Mahajan,et al.  Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis , 2018, European heart journal.

[6]  G. Fonarow,et al.  International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD‐AF, ORBIT‐AF I, and ORBIT‐AF II registries , 2017, American heart journal.

[7]  G. Lip,et al.  Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Elect , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  Panos Vardas,et al.  Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial , 2017, American heart journal.

[9]  M. Link,et al.  2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.

[10]  Philippe Mabo,et al.  Rationale and design of the Apixaban for the Reduction of Thrombo‐Embolism in Patients With Device‐Detected Sub‐Clinical Atrial Fibrillation (ARTESiA) trial , 2017, American heart journal.

[11]  A. Capucci,et al.  Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT , 2017, European heart journal.

[12]  Renato Pietro Ricci,et al.  HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. , 2015, Heart rhythm.

[13]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[14]  A. Verma,et al.  Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position statement on the use of remote monitoring for cardiovascular implantable electronic device follow-up. , 2013, The Canadian journal of cardiology.

[15]  A. Brandes,et al.  Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. , 2012, Heart rhythm.

[16]  Mårten Rosenqvist,et al.  Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.

[17]  A. Boyle,et al.  The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts. , 2011, Journal of the American College of Cardiology.

[18]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[19]  E. Aliot,et al.  Indications for the use of diagnostic implantable and external ECG loop recorders. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[20]  A. Capucci,et al.  Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events , 2009, Journal of cardiovascular electrophysiology.

[21]  A. Raviele,et al.  Recurrent unexplained palpitations (RUP) study comparison of implantable loop recorder versus conventional diagnostic strategy. , 2007, Journal of the American College of Cardiology.

[22]  Massimo Santini,et al.  Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. , 2005, Journal of the American College of Cardiology.